Auditory Intranerve Stimulation Study (AIS)
Intraoperative Acute Study to Evaluate Auditory Intranerve Stimulation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Karl-Heinz Dyballa
- Phone Number: +4917615328589
- Email: dyballa.karl-heinz@mh-hannover.de
Study Locations
-
-
-
Hannover, Germany, 30625
- Recruiting
- Hannover Medical School
-
Contact:
- Karl-Heinz Dyballa
- Email: dyballa.karl-heinz@mh-hannover.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent
- Patients who will undergo an acoustic neuroma removal surgery and are functional deaf
- Age ≥ 18 years
- Women with childbearing potential: willingness to use a reliable contraceptive method (e.g. copper intrauterine devices or hormonal methods) after consulting their gyncecologists
Exclusion Criteria:
- Disabilities in addition to hearing impairment which might interfere with the study procedure
- Pregnant and breast feeding woman or other vulnerable population
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Insert Array Into Auditory Nerve
|
To measure eABRs when stimulating the human auditory nerve
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Elicit a typical eABR Wave V with at least 0.2 µV in amplitude and a latency of the peak around 5 ms
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Collection of adverse events
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Thomas Lenarz, Prof. Prof. Dr., Hannover Medical School, Director of otorhinolaryngology
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AIS-001
- CIV-22-05-039592 (Other Grant/Funding Number: Blackrock Neurotech)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.